Invivyd reports Phase 3 LIBERTY trial shows its low-dose antibody VYD2311 is safer and better tolerated than Pfizer’s Covid vaccine
Invivyd, a small biotech focused on an injectable monoclonal antibody as an alternative to Covid vaccines, has released new data from its Phase 3 LIBERTY study.
The trial compared the company’s candidate, VYD2311, with Pfizer’s mRNA vaccine Comirnaty and found VYD2311 to have superior safety and tolerability profiles over the six‑day observation period.
While the positive readout could improve the company’s standing with investors and partners, the pathway to FDA approval remains uncertain, and further regulatory review will be required before the product can reach the market.
This writeup was produced by pharmadog from original reporting by STAT.
Original headline: “STAT+: Invivyd’s pursuit of a Covid vaccine alternative gets a lift, but an FDA hurdle may await”
read at STAT ↗
comments(0)
5-min edit window · permanent after that